Cost regulators have now published final guidance endorsing routine NHS use of Bayer’s Eylea for all patients with visual impairment due to branch retinal vein occlusion (BRVO), having initially recommended its use only in the second-line setting.
Read More
Cost regulators are now backing NHS use of Bayer’s Eylea for all patients with visual impairment due to branch retinal vein occlusion (BRVO), having initially recommended its use only in the second-line setting.
Read More
Bayer says it is disappointed that the National Institute for Health and Care Excellence is supporting NHS use of anti-VEGF therapy Eylea to treat a common cause of visual impairment only in the second-line setting.
Read More
